Insmed Incorporated (INSM +2%) gains after the FDA grants orphan drug designation to Arikace, an...

|By:, SA News Editor

Insmed Incorporated (INSM +2%) gains after the FDA grants orphan drug designation to Arikace, an inhaler for treating infections caused by non-tuberculous mycobacteria. The company notes that there's currently no FDA-approved treatment for this particular NTM lung infection.